Hinge Health, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
HNGE$123.23+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net income (loss) | $136,217 | $(560,356) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 4,455 | 3,910 |
| Stock-based compensation | 50,324 | 625,837 |
| Amortization of deferred commissions | 57,006 | 32,436 |
| Accretion of discounts and amortization of premiums on marketable securities, net | 1,255 | 376 |
| Non-cash operating lease expense | 2,986 | 2,549 |
| Provision for credit losses | 2,527 | 3,340 |
| Deferred taxes | (3,300) | 146 |
| Other | (2) | 2 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (79,402) | (47,610) |
| Deferred commissions | (74,246) | (38,320) |
| Inventory | (3,251) | (2,939) |
| Prepaid expenses and other current assets | (1,915) | (8,002) |
| Other assets | 165 | (8,149) |
| Accounts payable and accrued liabilities | 12,590 | 24,990 |
| Operating lease liabilities | (3,052) | (2,724) |
| Deferred revenue | 156,741 | 82,062 |
| Net cash provided by operating activities | 259,098 | 107,548 |
| Investing activities: | ||
| Purchase of property and equipment | (582) | (300) |
| Capitalized internal use software | (4,746) | (3,401) |
| Purchases of marketable securities | (89,877) | (318,180) |
| Maturities of marketable securities | 214,117 | 249,814 |
| Acquisition of a business, net of cash acquired | (97,353) | (4,000) |
| Cash paid for an asset acquisition | (9,036) | — |
| Net cash provided by (used in) investing activities | 12,523 | (76,067) |
| Financing activities: | ||
| Proceeds from exercise of common stock options | 882 | 787 |
| Issuance of common stock in connection with the employee stock purchase plan | 7,276 | — |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs | — | 255,675 |
| Repurchase and retirement of common stock | (157,384) | — |
| Tax withholdings on settlement of restricted stock units and performance-based restricted stock units | (116,356) | (272,258) |
| Payment on Repurchase Agreement with Coatue | — | (50,000) |
| Proceeds from repayment of non-recourse loans to employees | — | 4,934 |
| Payments for deferred offering costs | — | (10,061) |
| Net cash used in financing activities | (265,582) | (70,923) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 6,039 | (39,442) |
| Cash, cash equivalents, and restricted cash, beginning of period | 209,796 | 302,586 |
| Cash, cash equivalents, and restricted cash, end of period | $215,835 | $263,144 |
| Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $211,553 | $261,342 |
| Restricted cash | 4,282 | 1,802 |
| Total cash, cash equivalents, and restricted cash | $215,835 | $263,144 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $3,649 | $1,210 |
| Supplemental disclosures of noncash investing and financing activities: | ||
| Stock-based compensation capitalized in internal-use software | $908 | $600 |
| Conversion of redeemable convertible preferred stock Series E to common stock | $199,874 | $— |
| Right-of-use assets obtained in exchange for lease obligation | $29,441 | $686 |
| Unpaid excise tax at the end of the period on repurchase and retirement of common stock included in additional paid in capital | $85 | $— |
| Property and equipment purchased and unpaid at end of period | $57 | $— |
| Unpaid deferred offering costs at period end | $— | $538 |
| Conversion of redeemable convertible preferred stock for Coatue in connection with initial public offering | $— | $150,694 |
| Conversion of redeemable convertible preferred stock for all other in connection with initial public offering | $— | $346,530 |
| Adjustment to reflect deemed contribution from Series D and E redeemable convertible preferred stock extinguishment | $— | $104,174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.